Prevalence and incidence of mycoplasma genitalium: a systematic review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
The objective of this review is to determine the prevalence and incidence of Mycoplasma genitalium. Mycoplasma genitalium is a sexually transmitted pathogen that can cause reproductive health issues in both men and women. Recent US Food and Drug Administration (FDA)-approved testing has improved the capability to more readily diagnose and treat this infection. Determining the incidence and prevalence of this sexually transmitted infection is imperative to better understand the epidemiologic implications, and long-term consequences of this disease process. Studies on males and females of any age, race, or cultural background will be included. Studies conducted in any setting or geographical location that report on prevalence or incidence of Mycoplasma genitalium diagnosed by the FDA-approved Aptima Mycoplasma genitalium assay will be included. The proposed systematic review will be conducted in accordance with JBI methodology for systematic reviews of prevalence and incidence, and in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. MEDLINE (PubMed), CINAHL (EBSCOhost), Embase, Web of Science, and Global Infectious Diseases and Epidemiology Network (GIDEON) databases will be searched with no date limits. Prevalence and incidence data, experimental, quasi-experimental, observational, and descriptive studies will be included and critically appraised by 2 independent reviewers. Data will be extracted using standardized JBI data extraction tools. If sufficient data are available, a meta-analysis will be conducted; otherwise, the findings will be presented in narrative format, including tables and figures, to aid in data presentation, where appropriate. PROSPERO CRD42023415457.
Identifiants
pubmed: 37909115
doi: 10.11124/JBIES-23-00181
pii: 02174543-990000000-00230
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 JBI.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
De Carvalho NS, Palu G, Witkin SS. Mycoplasma genitalium, a stealth female reproductive tract. Eur J Clin Microbiol Infect Dis 2020;39:229–234.
Yu J, Zhou Y, Luo H, Su X, Gan T, Wang J, et al. Mycoplasma genitalium infection in the female reproductive system: disease and treatment. Front Microbiol 2023;14:1–12.
Sena AC, Lee JY, Schwebke J, Philip SS, Wiesenfeld HC, Rompalo AM, et al. A silent epidemic: the prevalence, incidence and persistence of mycoplasma genitalium among young, asymptomatic high-risk women in the United States. Clin Infect Dis 2018;67(1):73–79.
Manhart LE, Gaydos CA, Taylor SN, Lillis RA, Hook IIIEW, Klausner JD, et al. Characteristics of Mycoplasma genitalium urogenital infections in a diverse patient sample from the Unites States: results from the Aptima Mycoplasma genitalium evaluation study (AMES). J Clin Microbiol 2020;58(7):e00165–20.
Herms F, Poizeau F, Anyfantakis V, Bonhomme P, Chaine-Sidibe A, Louison J, et al. Mycoplasma genitalium screening in a specialized French unit: a retrospective study. Ann Dermatol Venereol 2022;149(3):165–168.
Tuddenham A, Hamill MM, Ghanem Kg. Diagnosis and treatment of sexually transmitted infection. JAMA 2022;327(2):161–172.
Napierala Mavedzenge S, Weiss HA. Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS 2009;25(5):611–620.
Roxby AC, Yuhas K, Farquar C, Bosire R, Mbori-Ngacha D, Richarson BA. Mycoplasma genitalium infection among HIV-infected pregnant African women and implications for mother-to-child transmission of HIV. AIDS 2019;33:2211–2217.
U.S. Food and Drug Administration. FDA permits marketing of first test to aid in the diagnosis of a sexually-transmitted infection known as Mycoplasma genitalium [internet]. FDA; 2019 [cited 2023 Mar 18]. Available from: https://cacmap.fda.gov/news-events/press-announcements/fda-permits-marketing-first-test-aid-diagnosis-sexually-transmitted-infection-known-mycoplasma.
Centers for Disease Control. Core elements of antibiotic stewardship [internet]. CDC; 2021. [cited 2023 Mar 16]. Available from: https://www.cdc.gov/antibiotic-use/core-elements/index.html.
Centers for Disease Control. Mycoplasma genitalium-CDC basic fact sheet [internet]. CDC; 2022 [cited 2023 Mar 22]. Available from: https://www.cdc.gov/std/mgen/stdfact-Mgen.htm.
Bachman LH, Kirkcaldy RD, Geisler WM, Wiesenfeld HC, Manhart LE, Taylor SN, et al. Prevalence of mycoplasma genitalium infection, antimicrobial resistance mutations, and symptoms resolution following treatment of urethritis. Clin Infect Dis 2020;15:71.
Gaydos CA, Manhart LE, Taylor SN, Lillis RA, Hook EW, Klausner JD, et al. Molecular testing for mycoplasma genitalium in the United States: results from AMES prospective multicentre clinical study. J Clin Microbiol 2019;57(11):1–12.
Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer GR, et al. Prevalence of Mycoplasma genitalium in different population groups: systemic review and meta-analysis. Epidemiol 2018;94(4).
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C Aromataris E, Munn Z. Chapter 5: Systematic reviews of prevalence and incidence [internet]. JBI Manual for Evidence Synthesis. JBI; 2020 [cited 2023 Mar 12]. Available from: https://synthesismanual.jbi.global.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906.
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc 2019;17(1):36–43.